Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIME-NL timing of immunotherapy in metastatic melanoma
NL-OMON61286Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of ipilimumab and nivolumab in cutaneous melanoma (CM) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Best overall response rate. Started Aug 2026; status: recruiting.
02
Drugs
ipilimumabnivolumab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NL-OMON61286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61286.